Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston
boston blog main
boston top stories
5
×
life sciences
5
×
national blog main
rna interference
5
×
alnylam pharmaceuticals
clinical trials
drugs
national top stories
san francisco blog main
aminolevulinic acid
barry greene
biotech
dan ollendorf
fda
givosiran
new york blog main
patisiran
san francisco top stories
accelerated approval
acute hepatic porphyria
acute hepatic porphyrias
akcea therapeutics
akin akinc
alexion pharmaceuticals
alnylam pharmaceutials
amy schulman
andreas klein
anna greka
arrowhead pharmaceuticals
boehringer ingelheim
boston university
car-t
caron jacobson
cigall kadoch
craig mello
deals
dicerna pharmaceuticals
eli lilly
What
rna
5
×
interference
ago
alnylam
medicine
rnai
drug
fda
market
medicines
pharmaceuticals
second
seek
speedy
abandoning
approval
approve
aren’t
awaits
baggage
biological
car
cleared
companies
crossed
cuts
cutting
data
deal
decades
decision
development
dicerna
discovered
edge
experiments
far
fingers
free
friday
Language
Current search:
rna
×
" rna interference "
×
" life sciences "
×
" boston top stories "
×
@xconomy.com
5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision
@xconomy.com
6 years ago
CAR-T’s Launch, Payers vs. Gene Therapy & Photos From “What’s Hot”